{"disease":{"id":"metastatic-stage-iv-breast-cancer","name":"metastatic stage iv breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04526587","title":"Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT07030569","title":"RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03418961","title":"S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":491,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT02595905","title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01048918","title":"Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":280,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05215769","title":"A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":243,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT03199885","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04297384","title":"Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04906369","title":"Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring","phase":"","overall_status":"SUSPENDED","enrollment_count":150,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01622868","title":"Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04316117","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02364557","title":"Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT02657889","title":"Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Tesaro, Inc.","has_results":true},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01142401","title":"Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03455270","title":"G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03823144","title":"Intravital Microscopy in Human Solid Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06439693","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03281902","title":"Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06405828","title":"Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT04090567","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02713269","title":"Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT04521764","title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04771520","title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02778685","title":"Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":47,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT05092373","title":"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04305834","title":"Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01463072","title":"Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT03579472","title":"M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03603197","title":"BP-C1 in Short-term Treatment of Thai Patients With Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Meabco A/S","has_results":false},{"nct_id":"NCT01638533","title":"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02783794","title":"BP-C1 in Short-term Treatment of Patients With Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Meabco A/S","has_results":false},{"nct_id":"NCT03691493","title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT01351909","title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03101748","title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":34,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02474173","title":"Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06246968","title":"A Study of Pembrolizumab and Cryoablation in People With Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03789019","title":"BP-C1 Monotherapy in Patients With Metastatic Breast Cancer Cancer: Estimation of Optimal Duration of Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Meabco A/S","has_results":false},{"nct_id":"NCT03291938","title":"IACS-010759 in Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06678269","title":"A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03853707","title":"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04445844","title":"INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":25,"lead_sponsor_name":"Mridula George, MD","has_results":false},{"nct_id":"NCT05098210","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03524170","title":"Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04348747","title":"Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT03218826","title":"PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03106415","title":"Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Mayo Clinic","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}